Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

T J De Wolfe; S Eggers; A K Barker; A E Kates; K A Dill-McFarland; G Suen; N Safdar

doi:10.1371/journal.pone.0204253

Back

Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

Journal article

Open access

Peer reviewed

Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

T J De Wolfe, S Eggers, A K Barker, A E Kates, K A Dill-McFarland, G Suen and N Safdar

PloS one, Vol.13(9), pp.e0204253-e0204253

09/28/2018

DOI: 10.1371/journal.pone.0204253

PMCID: PMC6161886

PMID: 30265691

Files and links (1)

url

https://doi.org/10.1371/journal.pone.0204253View

Published (Version of record) Open Access

Abstract

Perturbations in the gastrointestinal microbiome caused by antibiotics are a major risk factor for Clostridium difficile infection (CDI). Probiotics are often recommended to mitigate CDI symptoms; however, there exists only limited evidence showing probiotic efficacy for CDI. Here, we examined changes to the GI microbiota in a study population where probiotic treatment was associated with significantly reduced duration of CDI diarrhea. Subjects being treated with standard of care antibiotics for a primary episode of CDI were randomized to probiotic treatment or placebo for 4 weeks. Probiotic treatment consisted of a daily multi-strain capsule (Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 1010 CFUs. Stool was collected and analyzed using 16S rRNA sequencing. Microbiome analysis revealed apparent taxonomic differences between treatments and timepoints. Subjects administered probiotics had reduced Verrucomicrobiaceae at week 8 compared to controls. Bacteroides were significantly reduced between weeks 0 to 4 in probiotic treated subjects. Ruminococcus (family Lachnospiraceae), tended to be more abundant at week 8 than week 4 within the placebo group and at week 8 than week 0 within the probiotic group. Similar to these results, previous studies have associated these taxa with probiotic use and with mitigation of CDI symptoms. Compositional prediction of microbial community function revealed that subjects in the placebo group had microbiomes enriched with the iron complex transport system, while probiotic treated subjects had microbiomes enriched with the antibiotic transport system. Results indicate that probiotic use may impact the microbiome function in the face of a CDI; yet, more sensitive methods with higher resolution are warranted to better elucidate the roles associated with these changes. Continuing studies are needed to better understand probiotic effects on microbiome structure and function and the resulting impacts on CDI.

Administration, Oral

Anti-Bacterial Agents - adverse effects

Anti-Bacterial Agents - therapeutic use

Bifidobacterium - physiology

Clostridium Infections - drug therapy

Gastrointestinal Microbiome - drug effects

Humans

Lactobacillus - physiology

Probiotics - administration & dosage

Probiotics - pharmacology

Details

Title: Subtitle: Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection
Creators: T J De Wolfe - University of Pittsburgh
S Eggers - University of Wisconsin–Madison
A K Barker - University of Wisconsin–Madison
A E Kates - University of Wisconsin–Madison
K A Dill-McFarland - University of Wisconsin–Madison
G Suen - University of Wisconsin–Madison
N Safdar - University of Wisconsin–Madison
Resource Type: Journal article
Publication Details: PloS one, Vol.13(9), pp.e0204253-e0204253
DOI: 10.1371/journal.pone.0204253
PMID: 30265691
PMCID: PMC6161886
NLM abbreviation: PLoS One
ISSN: 1932-6203
eISSN: 1932-6203
Grant note: name: U.S. Department of Agriculture (US), award: WIS01729; DOI: 10.13039/100000002, name: National Institutes of Health, award: 1R03AG040669-01A1
Language: English
Date published: 09/28/2018
Academic Unit: Epidemiology; Injury Prevention Research Center
Record Identifier: 9984446559602771

Metrics

13 Record Views

39 Times Cited - Web of Science